Unione Europea - italiano - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sclerosi multipla - immunosoppressori selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - natalizumabum - concentrato per soluzione per infusione - natalizumabum 300 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml corresp. natrium 52 mg. - multiple sklerose - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - sclerosi multipla recidivante-remittente - immunosoppressori - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - natalizumabum - injektionslösung in einer fertigspritze - natalizumabum 150 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.45 mg. - multiple sklerose - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Unione Europea - italiano - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant può essere usato in monoterapia o in combinazione con metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - mitoxantrone - mitoxantrone

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - leflunomidum - compresse rivestite con film - leflunomidum 10 mg, excipiens pro compresso haze. - polyarthrite rhumatoïde attivo - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - leflunomidum - compresse rivestite con film - leflunomidum 20 mg, excipiens pro compresso haze. - polyarthrite rhumatoïde attivo - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - leflunomidum - compresse rivestite con film - leflunomidum 100 mg, excipiens pro compresso haze. - polyarthrite rhumatoïde attivo - synthetika